NAGIOS: RODERIC FUNCIONANDO

Elevated plasma level of visfatin/pre-b cell colony-enhancing factor in male oral squamous cell carcinoma patients

Repositori DSpace/Manakin

IMPORTANT: Aquest repositori està en una versió antiga des del 3/12/2023. La nova instal.lació está en https://roderic.uv.es/

Elevated plasma level of visfatin/pre-b cell colony-enhancing factor in male oral squamous cell carcinoma patients

dc.contributor.author	Yu Duan, Tsai	es
dc.contributor.author	Chao Ping, Wang	es
dc.contributor.author	Chih Yu, Chen	es
dc.contributor.author	Li Wen, Lin	es
dc.contributor.author	Tsun Mei, Lin	es
dc.contributor.author	Chia Chang, Hsu	es
dc.contributor.author	Fu Mei, Chung	es
dc.contributor.author	Hsien Chang, Lin	es
dc.contributor.author	Hsia Fen, Hsu	es
dc.contributor.author	Yau Jiunn, Lee	es
dc.contributor.author	Jer Yiing, Houng	es
dc.date.accessioned	2014-05-29T07:04:53Z
dc.date.available	2014-05-29T07:04:53Z
dc.date.issued	2013	es
dc.identifier.citation	Yu Duan, Tsai ; Chao Ping, Wang ; Chih Yu, Chen ; Li Wen, Lin ; Tsun Mei, Lin ; Chia Chang, Hsu ; Fu Mei, Chung ; Hsien Chang, Lin ; Hsia Fen, Hsu ; Yau Jiunn, Lee ; Jer Yiing, Houng. Elevated plasma level of visfatin/pre-b cell colony-enhancing factor in male oral squamous cell carcinoma patients. En: Medicina oral, patología oral y cirugía bucal. Ed inglesa, 2013, Vol. 18, No. 2: 180-186	es
dc.identifier.uri	http://hdl.handle.net/10550/35578
dc.description.abstract	Objectives: Visfatin, also known as nicotiamide phosphoribosyltransferase or pre-B cell colony enhancing factor, is a pro-inflammatory cytokine whose serum level is increased in various cancers. In this study, we investigated whether plasma visfatin levels were altered in patients with oral squamous cell carcinoma (OSCC). The relation ship between plasma visfatin levels and the pretreatment hematologic profile was also explored. Study Design: Plasma visfatin concentrations were measured through ELISA in OSCC patients and control sub- D esign: Plasma visfatin concentrations were measured through ELISA in OSCC patients and control sub- esign: Plasma visfatin concentrations were measured through ELISA in OSCC patients and control sub jects. A total of 51 patients with OSCC and 57 age- and body mass index (BMI)-matched control subjects were studied. All study subjects were male. Results: Plasma visfatin was found to be elevated in patients with OSCC (7.0 ± 4.5 vs. 4.8 ± 1.9 ng/ml, p = 0.002). Multiple logistic regression analysis revealed visfatin as an independent association factor for OSCC, even after full adjustment of known biomarkers. Visfatin level was significantly correlated with white blood cell (WBC) count, neutrophil count, and hematocrit (all p < 0.05). In addition, WBC count, neutrophil count, and visfatin gradually increased with stage progression, and hematocrit gradually decreased with stage progression (all p < 0.05). Conclusion: Increased plasma visfatin levels were associated with OSCC, independent of risk factors, and were cor related with inflammatory biomarkers. These data suggest that visfatin may act through inflammatory reactions to play an important role in the pathogenesis of OSCC	en_US
dc.subject	Odontología	es
dc.subject	Ciencias de la salud	es
dc.title	Elevated plasma level of visfatin/pre-b cell colony-enhancing factor in male oral squamous cell carcinoma patients	es
dc.type	journal article	es_ES
dc.subject.unesco	UNESCO::CIENCIAS MÉDICAS	es
dc.type.hasVersion	VoR	es_ES